Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ShinRui (disodium levoornidazole phosphate for injection) in postoperative intra-abdominal anaerobic infections
CTR20223205Phase 4Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of levornidazole in Postoperative intra-abdominal infection (PIAI), amebiasis and postoperative anaerobic infection (2 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Clinical cure rate at 5–10 days after end of study treatment and First clinical outcome assessment within 5–10 days after end of treatment. Started Dec 2022; status: completed.
02
Drugs
levornidazole
03
Conditions
Postoperative intra-abdominal infection (PIAI)amebiasispostoperative anaerobic infection
Beyond the preview
Go deeper on CTR20223205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223205.